The majority of published studies of GLP-1 medicines in experimental neurodegeneration demonstrate therapeutic activity for GLP-1RAs, including those carried out in mouse models of Alzheimer's disease [39]. This evidence concerns the gene GLP1R and early-onset autosomal dominant Alzheimer disease.